A method for detecting enantiomers of dexmedetomidine hydrochloride injection
By using Chiralcel OD-RH column and area normalization method in the detection of dexmedetomidine hydrochloride injection, the problem of filler denaturation caused by large concentration of salt was solved, and the accuracy of enantiomer detection was achieved and Simplicity improves detection efficiency.
Patent Information
- Application Number
- CN202211097151.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-09-08
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2042-09-08
AI Technical Summary
The existing enantiomer detection methods for dexmedetomidine hydrochloride injection have problems such as large concentrations of salt causing filler denaturation, cumbersome detection methods and inaccurate results.
High performance liquid chromatography was used, using Chiralcel OD-RH chromatography column and acetonitrile-potassium hexafluorophosphate solution as mobile phases, and the enantiomer content was calculated by combining the area normalization method, which avoided the influence of large concentrations of salt on the filler and Simplified the detection process.
It improves the accuracy and efficiency of detection, avoids the operation of quantification calibration, and ensures the reliability of the analysis results.
Smart Images

Figure CN115616104B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of drug analysis, and specifically relates to a method for detecting enantiomers of dexmedetomidine hydrochloride injection. Background Art
[0002] Dexmedetomidine hydrochloride injection is an α2-adrenaline receptor agonist. It has central anti-sympathetic and anti-anxiety effects, and can produce a sedative effect similar to natural sleep. It is mainly used clinically for sedation during endotracheal intubation and mechanical ventilation in surgical patients undergoing general anesthesia. It can also be used to regulate the endocrine regulation of perioperative stress response, reduce the incidence of delirium in ICU patients, and reduce the occurrence of arrhythmias.
[0003] Dexmedetomidine hydrochloride injection is a small-volume injection, and the prescription composition of its unit dose product is: 236ug dexmedetomidine hydrochloride, 18mg sodium chloride, and 2.0ml water for injection.
[0004] The existing detection method of dexmedetomidine hydrochloride injection enantiomers (levomedetomidine) has the following problems in application: first, the calculation method is an external standard method, which requires a reference substance for qualitative and quantitative research, and requires accurate calibration of the content, which is relatively cumbersome; second, the chromatographic column used in the method is a protein column AGP (reverse chiral column), under which the separation of dexmedetomidine and levomedetomidine is good, but the solvent of dexmedetomidine hydrochloride injection is 0.9% sodium chloride solution. When the AGP chromatographic column is used for detection, a large concentration of salt denatures the filler, resulting in a situation where the column pressure is high, the separation is significantly reduced, and the column efficiency is reduced, resulting in inaccurate analysis results. Based on this, it is necessary to invent a detection method for dexmedetomidine hydrochloride injection enantiomers, which is simple and fast, and the detection result is accurate. Summary of the invention
[0005] The invention provides a method for detecting the enantiomers of dexmedetomidine hydrochloride injection in order to solve the problems that a high concentration of salt denatures a filler and the detection method is complicated, resulting in inaccurate detection results.
[0006] The present invention is achieved by adopting the following technical solutions:
[0007] A method for detecting enantiomers of dexmedetomidine hydrochloride injection comprises the following steps:
[0008] Test solution: dexmedetomidine hydrochloride injection;
[0009] Chromatographic conditions: high performance liquid chromatography; Chiralcel OD-RH column, cellulose-tris (3,5-dimethylphenylcarbamate) coated silica gel as filler; acetonitrile-potassium hexafluorophosphate solution (35:65) as mobile phase; flow rate of 0.5 ml / min; injection volume of 10 μl; detection wavelength of 220 nm; column temperature of 30 °C; running time of 25 min;
[0010] Chromatographic peak determination: Inject the test sample solution into the HPLC, record the chromatogram, and calculate the content of the enantiomer in the test sample by area normalization method.
[0011] Further preferably, the concentration of the potassium hexafluorophosphate solution in the mobile phase is 0.1 mol / l, and the pH value is adjusted to 3.0 with phosphoric acid.
[0012] Further preferably, the specification of the chromatographic column is 150×4.6 mm, and the particle size is 5 μm.
[0013] Further preferably, before injecting the test solution into the high performance liquid chromatograph, a blank sample and a system suitability solution are respectively injected into the high performance liquid chromatograph for a system suitability test, and the injection volume is 10 μl;
[0014] The blank sample is a diluent;
[0015] The preparation process of the system adaptability solution is as follows: take an appropriate amount of dexmedetomidine hydrochloride reference substance and an appropriate amount of enantiomer reference substance, dissolve and dilute with a diluent, and prepare a system adaptability solution with a dexmedetomidine concentration of 100 μg / ml and a levomedetomidine concentration of 0.1 μg / ml or 0.15 μg / ml;
[0016] The diluent is purified water;
[0017] The requirements for system adaptability are: when the system adaptability solution is tested, the peak order is dexmedetomidine and levomedetomidine, the separation between the two should be no less than 1.5, and the theoretical plate number calculated based on the dexmedetomidine peak should be no less than 2000.
[0018] The limit of the detection method of dexmedetomidine hydrochloride injection enantiomers described in the present invention is: if there is a chromatographic peak in the chromatogram of the test solution with the same retention time as levomedetomidine, it shall not be greater than 1.0% calculated by the area normalization method.
[0019] The invention provides a method for detecting enantiomers of dexmedetomidine hydrochloride injection. A Chiralcel OD-RH chromatographic column is adopted, the separation degree of dexmedetomidine and levomedetomidine is good, the problem that a high concentration of salt denatures a filler is avoided, the detection accuracy is improved, and the method is more suitable for detecting enantiomers of dexmedetomidine hydrochloride injection. Meanwhile, an area normalization method is adopted to calculate the content of the enantiomers of the dexmedetomidine injection, the operation of content calibration is omitted, the problem of complicated operation is avoided, and the detection efficiency is improved. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 is the HPLC chromatogram of the test solution in Example 1;
[0021] Figure 2 It is the HPLC chromatogram of the test solution in Comparative Example 1;
[0022] Figure 3 It is the HPLC chromatogram of the test solution in Comparative Example 2;
[0023] Figure 4 It is the HPLC chromatogram of the reference substance solution in Comparative Example 3;
[0024] Figure 5 It is the HPLC chromatogram of the test solution in Comparative Example 3. DETAILED DESCRIPTION
[0025] Example 1
[0026] A method for detecting enantiomers of dexmedetomidine hydrochloride injection comprises the following steps:
[0027] Step S1: Before injecting the test solution into the high performance liquid chromatograph, first inject the blank sample and the system suitability solution into the high performance liquid chromatograph for system suitability test, and the injection volume is 10 μl;
[0028] The blank sample is a diluent;
[0029] The preparation process of the system adaptability solution is as follows: taking about 12 mg of dexmedetomidine hydrochloride reference substance, accurately weighing, placing in a 100 ml volumetric flask, adding water to dissolve, then accurately measuring 1 ml of levomedetomidine hydrochloride reference substance stock solution and placing in the volumetric flask, adding water to dilute to prepare a solution containing 0.12 mg of dexmedetomidine hydrochloride and 0.12 μg of levmedetomidine hydrochloride per 1 ml, that is, preparing a system adaptability solution with a dexmedetomidine concentration of 100 μg / ml and a levmedetomidine concentration of 0.1 μg / ml;
[0030] The diluent is purified water;
[0031] The requirements for system adaptability are: when the system adaptability solution is tested, the peak order is dexmedetomidine and levomedetomidine, the separation between the two should be no less than 1.5, and the theoretical plate number calculated based on the dexmedetomidine peak should be no less than 2000.
[0032] Step S2: test solution: dexmedetomidine hydrochloride injection;
[0033] Chromatographic conditions: high performance liquid chromatography; Chiralcel OD-RH chromatographic column, produced by Daicel Pharmaceutical Chiral Technology (Shanghai) Co., Ltd., with cellulose-tris (3,5-dimethylphenylcarbamate) coated silica gel as filler; the specification of the chromatographic column is 150×4.6mm, and the particle size is 5μm; the mobile phase is acetonitrile-0.1mol / l potassium hexafluorophosphate solution (adjusted to pH 3.0 with phosphoric acid) with a volume ratio of 35:65; the flow rate is 0.5ml / min; the injection volume is 10μl; the detection wavelength is 220nm; the column temperature is 30℃;
[0034] Chromatographic peak determination: Inject the test sample solution into the HPLC, record the chromatogram, and calculate the content of the enantiomer in the test sample by area normalization method.
[0035] Among them, the HPLC method is determined according to the high performance liquid chromatography method (General Rules 0512 of Part IV of the 2020 Edition of the Chinese Pharmacopoeia).
[0036] The HPLC chromatogram of the test solution in this example is shown in the attached figure. Figure 1 The chromatographic peak results are shown in Table 1:
[0037] Table 1: Chromatographic peak results of the test solution in Example 1
[0038]
[0039] Example 2
[0040] A method for detecting enantiomers of dexmedetomidine hydrochloride injection comprises the following steps:
[0041] Step S1: Before injecting the test solution into the high performance liquid chromatograph, first inject the blank sample and the system suitability solution into the high performance liquid chromatograph for system suitability test, and the injection volume is 10 μl;
[0042] The blank sample is a diluent;
[0043] The preparation process of the system adaptability solution is as follows: take an appropriate amount of dexmedetomidine hydrochloride reference substance and an appropriate amount of enantiomer reference substance, dissolve and dilute with a diluent, and prepare a system adaptability solution with a dexmedetomidine concentration of 100 μg / ml and a levomedetomidine concentration of 0.15 μg / ml;
[0044] The diluent is purified water;
[0045] The requirements for system adaptability are: when the system adaptability solution is tested, the peak order is dexmedetomidine and levomedetomidine, the separation between the two should be no less than 1.5, and the theoretical plate number calculated based on the dexmedetomidine peak should be no less than 2000.
[0046] Step S2: test solution: dexmedetomidine hydrochloride injection;
[0047] Chromatographic conditions: high performance liquid chromatography; Chiralcel OD-RH column, cellulose-tris (3,5-dimethylphenylcarbamate) coated silica gel as filler; column size 150×4.6 mm, particle size 5 μm; acetonitrile-0.1 mol / l potassium hexafluorophosphate solution (pH adjusted to 3.0 with phosphoric acid) in a volume ratio of 35:65 as mobile phase; flow rate 0.5 ml / min; injection volume 10 μl; detection wavelength 220 nm; column temperature 30°C;
[0048] Chromatographic peak determination: Inject the test sample solution into the HPLC, record the chromatogram, and calculate the content of the enantiomer in the test sample by area normalization method.
[0049] Comparative Example 1
[0050] The only difference between this comparative example and Example 1 is that the chromatographic column is CHIRALCEL OD-H; the other experimental conditions and experimental operation steps are the same as those in Example 1.
[0051] The HPLC chromatogram of the test solution in this comparative example is shown in the attached Figure 2 The chromatographic peak results are shown in Table 2:
[0052] Table 2: Chromatographic peak results of the test solution in comparative example 1
[0053]
[0054]
[0055] Comparative Example 2
[0056] The only difference between this comparative example and Example 1 is that the chromatographic column is CHIRALPAK-AGP; the other experimental conditions and experimental operation steps are the same as those in Example 1.
[0057] The HPLC chromatogram of the test solution in this comparative example is shown in the attached Figure 3 The chromatographic peak results are shown in Table 3:
[0058] Table 3: Chromatographic peak results of the test solution of Comparative Example 2
[0059]
[0060] It can be seen from the experimental results of Example 1, Comparative Example 1 and Comparative Example 2 that the normal phase column CHIRALCEL OD-H normal phase system (n-hexane and ethanol) can achieve good separation of dexmedetomidine hydrochloride and levomedetomidine hydrochloride, but considering that the dexmedetomidine hydrochloride injection is an aqueous solution, it is not appropriate to select the normal phase column CHIRALCEL OD-H. The USP40 method uses a protein column CHIRALPAK-AGP (reverse chiral column) as the chromatographic column. Under this chromatographic column, the separation degree of dexmedetomidine and levomedetomidine is good, but the solvent of the dexmedetomidine hydrochloride injection is 0.9% sodium chloride solution. When the CHIRALPAK-AGP chromatographic column is used for detection, the high concentration of salt will denature the filler, resulting in a situation where the column pressure is high, the separation degree is significantly reduced, and the column efficiency is reduced, resulting in inaccurate analysis results, so it is not suitable to use the CHIRALPAK-AGP column. In summary, the comparison of the three chromatographic columns shows that the reversed-phase chiral column Chiralcel OD-RH chromatographic column is more suitable for the detection of enantiomers of dexmedetomidine hydrochloride injection.
[0061] Comparative Example 3
[0062] The difference between this comparative example and Example 1 is that: the content of enantiomers in the test sample is calculated by the external standard method; the test sample solution adopts a solution prepared from raw materials. Among them, the preparation method of the reference solution is: take an appropriate amount of levmedetomidine hydrochloride reference substance, accurately weigh it, dissolve it in water and dilute it to make a solution containing 0.5ug / ml of levmedetomidine per 1ml. The preparation method of the test solution is: take an appropriate amount of dexmedetomidine hydrochloride, accurately weigh it, dissolve it in water and dilute it to make a solution containing 0.1mg / ml of dexmedetomidine per 1ml.
[0063] The HPLC chromatogram of the reference solution in this comparative example is shown in the attached Figure 4 The HPLC chromatogram of the test solution is shown in the attached Figure 5 The chromatographic peak results are shown in Table 4:
[0064] Table 4: Comparison results between external standard method and area normalization method
[0065]
[0066] From the attached Figure 4 , Attachment Figure 5As shown in Table 4, the enantiomer peaks at around 10.5 min. Calculated by the area normalization method, the enantiomer content in the test solution is 0.027%, and the result calculated by the external standard method is 0.029%. The results are not much different and are both less than the limit of the supplier's method (0.15%). Therefore, the enantiomer content is calculated by the area normalization method.
[0067] Comparative Example 4
[0068] With reference to the fourth guideline 9101 (Guidelines for Validation of Analytical Methods) of the 2020 edition of the Chinese Pharmacopoeia, this comparative example conducted a methodological validation of the detection method of the enantiomers of dexmedetomidine hydrochloride injection described in the present invention, and the validation results are shown in Table 5;
[0069] Table 5: Methodology validation results
[0070]
[0071]
[0072]
[0073] The verification showed that this method was suitable for the detection of enantiomers of dexmedetomidine hydrochloride injection and the method was good.
Claims
1. A method for detecting enantiomers of dexmedetomidine hydrochloride injection, characterized in that: The steps include: Test solution: dexmedetomidine hydrochloride injection; Chromatographic conditions: high performance liquid chromatography; Chiralcel OD-RH chromatographic column, cellulose-tris (3, 5-dimethylphenylcarbamate) coated silica gel as filler; acetonitrile-potassium hexafluorophosphate solution with a volume ratio of 35:65 as mobile phase; flow rate of 0.5 ml / min; injection volume of 10 µl; detection wavelength of 220 nm; column temperature of 30 ° C; the specifications of the chromatographic column are 150×4.6 mm, and the particle size is 5 μm; Chromatographic peak determination: Inject the test sample solution into the HPLC, record the chromatogram, and calculate the content of the enantiomer in the test sample by area normalization method.
2. The method for detecting enantiomers of dexmedetomidine hydrochloride injection according to claim 1, characterized in that: The concentration of the potassium hexafluorophosphate solution in the mobile phase is 0.1 mol / l, and the pH value is adjusted to 3.0 with phosphoric acid.
3. The method for detecting enantiomers of dexmedetomidine hydrochloride injection according to claim 1, characterized in that: Before injecting the test solution into the HPLC, first inject the blank sample and system suitability solution into the HPLC for system suitability test, and the injection volume is 10μl; The blank sample is a diluent; The preparation process of the system adaptability solution is as follows: take an appropriate amount of dexmedetomidine hydrochloride reference substance and an appropriate amount of enantiomer reference substance, dissolve and dilute with a diluent, and prepare a system adaptability solution with a dexmedetomidine concentration of 100 µg / ml and a levomedetomidine concentration of 0.1 µg / ml or 0.15 µg / ml; The diluent is purified water; The requirements for system adaptability are: when the system adaptability solution is tested, the peak order is dexmedetomidine and levomedetomidine, the separation between the two should be no less than 1.5, and the theoretical plate number calculated based on the dexmedetomidine peak should be no less than 2000.
